{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:32:39Z","timestamp":1787614359202,"version":"build-2736575974"},"reference-count":131,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.cytogfr.2011.07.001","type":"journal-article","created":{"date-parts":[[2011,8,22]],"date-time":"2011-08-22T06:17:27Z","timestamp":1313993847000},"page":"177-187","source":"Crossref","is-referenced-by-count":19,"title":["Cytokine adjuvants for vaccine therapy of neoplastic and infectious disease"],"prefix":"10.1016","volume":"22","author":[{"given":"William K.","family":"Decker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Safdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"November 14 (18)","key":"10.1016\/j.cytogfr.2011.07.001_bib0005","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1001\/jama.298.18.2155","article-title":"Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States","volume":"298","author":"Roush","year":"2007","journal-title":"JAMA"},{"issue":"April (1)","key":"10.1016\/j.cytogfr.2011.07.001_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.20506\/rst.26.1.1724","article-title":"A brief history of vaccines and vaccination","volume":"26","author":"Lombard","year":"2007","journal-title":"Rev Sci Tech"},{"key":"10.1016\/j.cytogfr.2011.07.001_bib0015","series-title":"Princes and peasants: smallpox in history","author":"Hopkins","year":"1983"},{"key":"10.1016\/j.cytogfr.2011.07.001_bib0020","series-title":"Epidemiology and prevention of vaccine-preventable diseases","author":"Atkinson","year":"2005"},{"key":"10.1016\/j.cytogfr.2011.07.001_bib0025","series-title":"The greatest killer: smallpox in history","author":"Hopkins","year":"2002"},{"issue":"September (3)","key":"10.1016\/j.cytogfr.2011.07.001_bib0030","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1128\/MMBR.37.3.284-288.1973","article-title":"Agostino Bassi bicentennial (1773\u20131973)","volume":"37","author":"Porter","year":"1973","journal-title":"Bacteriol Rev"},{"issue":"8","key":"10.1016\/j.cytogfr.2011.07.001_bib0035","first-page":"383","article-title":"Pasteur\u2013Koch: distinctive ways of thinking about infectious diseases","volume":"2","author":"Ullmann","year":"2007","journal-title":"Microbe"},{"issue":"February (2)","key":"10.1016\/j.cytogfr.2011.07.001_bib0040","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.juro.2006.09.066","article-title":"Ignorance is bliss: the Listerian revolution and education of American surgeons","volume":"177","author":"Herr","year":"2007","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.cytogfr.2011.07.001_bib0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.25162\/medhist-2008-0005","article-title":"A matter of methods: the historicity of Koch's postulates 1840\u20132000","volume":"43","author":"Gradmann","year":"2008","journal-title":"Medizinhist J"},{"key":"10.1016\/j.cytogfr.2011.07.001_bib0050","series-title":"Principles and practice of infectious diseases","author":"Mandell","year":"2004"},{"issue":"July 15 (3)","key":"10.1016\/j.cytogfr.2011.07.001_bib0055","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/jama.2009.1024","article-title":"Development of hepatitis B vaccine","volume":"302","author":"Beasley","year":"2009","journal-title":"JAMA"},{"issue":"April (2)","key":"10.1016\/j.cytogfr.2011.07.001_bib0060","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.0818-9641.2003.01151.x","article-title":"Cancer immunotherapy: the past, the present and the future","volume":"81","author":"Parish","year":"2003","journal-title":"Immunol Cell Biol"},{"issue":"August (4)","key":"10.1016\/j.cytogfr.2011.07.001_bib0065","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cytogfr.2009.07.004","article-title":"Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited","volume":"20","author":"Decker","year":"2009","journal-title":"Cytokine Growth Factor Rev"},{"issue":"December (12)","key":"10.1016\/j.cytogfr.2011.07.001_bib0070","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/ni1141","article-title":"Plasmacytoid dendritic cells in immunity","volume":"5","author":"Colonna","year":"2004","journal-title":"Nat Immunol"},{"issue":"February (2)","key":"10.1016\/j.cytogfr.2011.07.001_bib0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bbmt.2005.09.003","article-title":"Dendritic cell immunotherapy for the treatment of neoplastic disease","volume":"12","author":"Decker","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"August 7 (8)","key":"10.1016\/j.cytogfr.2011.07.001_bib0080","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1084\/jem.20060401","article-title":"Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation","volume":"203","author":"Guiducci","year":"2006","journal-title":"J Exp Med"},{"issue":"January (1)","key":"10.1016\/j.cytogfr.2011.07.001_bib0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1128\/JVI.79.1.17-27.2005","article-title":"Plasmacytoid dendritic cells: linking innate and adaptive immunity","volume":"79","author":"McKenna","year":"2005","journal-title":"J Virol"},{"issue":"April 30 (18)","key":"10.1016\/j.cytogfr.2011.07.001_bib0090","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1182\/blood-2008-10-186890","article-title":"Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation","volume":"113","author":"Piccioli","year":"2009","journal-title":"Blood"},{"issue":"September (9)","key":"10.1016\/j.cytogfr.2011.07.001_bib0095","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1128\/AAC.48.9.3382-3389.2004","article-title":"Impact of alpha interferon and ribavirin on the function of maturing dendritic cells","volume":"48","author":"Barnes","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"November (11)","key":"10.1016\/j.cytogfr.2011.07.001_bib0100","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s00262-006-0140-z","article-title":"Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI)","volume":"55","author":"Schmidt","year":"2006","journal-title":"Cancer Immunol Immunother"},{"issue":"January (1)","key":"10.1016\/j.cytogfr.2011.07.001_bib0105","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/01.cji.0000211317.15278.27","article-title":"Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring","volume":"30","author":"Schmidt","year":"2007","journal-title":"J Immunother"},{"issue":"June 15 (Pt 3)","key":"10.1016\/j.cytogfr.2011.07.001_bib0110","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1042\/bj3320749","article-title":"Simultaneous binding of PA28 and PA700 activators to 20 S proteasomes","volume":"332","author":"Hendil","year":"1998","journal-title":"Biochem J"},{"issue":"January (1)","key":"10.1016\/j.cytogfr.2011.07.001_bib0115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/eji.200738098","article-title":"Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4","volume":"39","author":"Tosello","year":"2009","journal-title":"Eur J Immunol"},{"issue":"May 1 (9)","key":"10.1016\/j.cytogfr.2011.07.001_bib0120","first-page":"4943","article-title":"Immunization of stage IV melanoma patients with Melan-A\/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte\/dendritic cell precursors","volume":"66","author":"Di","year":"2006","journal-title":"Cancer Res"},{"issue":"August (8)","key":"10.1016\/j.cytogfr.2011.07.001_bib0125","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s00262-005-0084-8","article-title":"A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients","volume":"55","author":"Pilla","year":"2006","journal-title":"Cancer Immunol Immunother"},{"issue":"February 19 (9460)","key":"10.1016\/j.cytogfr.2011.07.001_bib0130","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"issue":"December (12)","key":"10.1016\/j.cytogfr.2011.07.001_bib0135","first-page":"3696","article-title":"Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha","volume":"8","author":"Vaishampayan","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"April 1 (7)","key":"10.1016\/j.cytogfr.2011.07.001_bib0140","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1158\/1078-0432.CCR-08-1752","article-title":"The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines","volume":"15","author":"Hance","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"November 15 (22)","key":"10.1016\/j.cytogfr.2011.07.001_bib0145","first-page":"5800","article-title":"A triad of costimulatory molecules synergize to amplify T-cell activation","volume":"59","author":"Hodge","year":"1999","journal-title":"Cancer Res"},{"issue":"April (7)","key":"10.1016\/j.cytogfr.2011.07.001_bib0150","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1128\/JVI.02000-10","article-title":"Antigen-specific T-cell responses to a recombinant fowlpox virus are dependent on MyD88 and interleukin-18 and independent of Toll-like receptor 7 (TLR7)- and TLR9-mediated innate immune recognition","volume":"85","author":"Lousberg","year":"2011","journal-title":"J Virol"},{"issue":"February 1 (4)","key":"10.1016\/j.cytogfr.2011.07.001_bib0155","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1200\/JCO.2005.10.206","article-title":"Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas","volume":"23","author":"Marshall","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cytogfr.2011.07.001_bib0160","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1479-5876-5-60","article-title":"Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer","volume":"5","author":"Kaufman","year":"2007","journal-title":"J Transl Med"},{"issue":"September 1 (5)","key":"10.1016\/j.cytogfr.2011.07.001_bib0165","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.4049\/jimmunol.0801607","article-title":"Type I interferon (IFN alpha) acts directly on human memory CD4+T cells altering their response to antigen","volume":"183","author":"Gallagher","year":"2009","journal-title":"J Immunol"},{"issue":"September 15 (39)","key":"10.1016\/j.cytogfr.2011.07.001_bib0170","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1016\/j.vaccine.2008.07.011","article-title":"The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines","volume":"26","author":"Thompson","year":"2008","journal-title":"Vaccine"},{"issue":"August 27 (39)","key":"10.1016\/j.cytogfr.2011.07.001_bib0175","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1016\/j.vaccine.2009.06.084","article-title":"Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans","volume":"27","author":"Couch","year":"2009","journal-title":"Vaccine"},{"issue":"April (4)","key":"10.1016\/j.cytogfr.2011.07.001_bib0180","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1099\/vir.0.006833-0","article-title":"Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection","volume":"90","author":"O\u2019Brien","year":"2009","journal-title":"J Gen Virol"},{"issue":"September 18 (41)","key":"10.1016\/j.cytogfr.2011.07.001_bib0185","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1016\/j.vaccine.2009.07.014","article-title":"Recombinant interferon-alpha2b improves immune response to hepatitis B vaccination in haemodialysis patients: results of a randomised clinical trial","volume":"27","author":"Miquilena-Colina","year":"2009","journal-title":"Vaccine"},{"issue":"March 1 (5)","key":"10.1016\/j.cytogfr.2011.07.001_bib0190","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.4049\/jimmunol.170.5.2269","article-title":"Cutting edge: histamine inhibits IFN-alpha release from plasmacytoid dendritic cells","volume":"170","author":"Mazzoni","year":"2003","journal-title":"J Immunol"},{"issue":"August 6 (36)","key":"10.1016\/j.cytogfr.2011.07.001_bib0195","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1016\/j.vaccine.2009.06.012","article-title":"Levamisole is a potential facilitator for the activation of Th1 responses of the subunit HBV vaccination","volume":"27","author":"Zhang","year":"2009","journal-title":"Vaccine"},{"issue":"April 21 (7036)","key":"10.1016\/j.cytogfr.2011.07.001_bib0200","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nature03547","article-title":"Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction","volume":"434","author":"Honda","year":"2005","journal-title":"Nature"},{"issue":"April 7 (7034)","key":"10.1016\/j.cytogfr.2011.07.001_bib0205","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nature03464","article-title":"IRF-7 is the master regulator of type-I interferon-dependent immune responses","volume":"434","author":"Honda","year":"2005","journal-title":"Nature"},{"issue":"September 1 (5)","key":"10.1016\/j.cytogfr.2011.07.001_bib0210","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.4049\/jimmunol.169.5.2368","article-title":"Distinct response of human B cell subpopulations in recognition of an innate immune signal CpG DNA","volume":"169","author":"Jung","year":"2002","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.cytogfr.2011.07.001_bib0215","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/11316930-000000000-00000","article-title":"CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer","volume":"23","author":"Murad","year":"2009","journal-title":"BioDrugs"},{"issue":"May 30","key":"10.1016\/j.cytogfr.2011.07.001_bib0220","article-title":"Marked enhancement of the immune response to BioThrax((R)) (anthrax vaccine adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers","author":"Rynkiewicz","year":"2011","journal-title":"Vaccine"},{"issue":"March 1 (5)","key":"10.1016\/j.cytogfr.2011.07.001_bib0225","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.4049\/jimmunol.0803596","article-title":"The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals","volume":"182","author":"Crompton","year":"2009","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.cytogfr.2011.07.001_bib0230","doi-asserted-by":"crossref","first-page":"e8787","DOI":"10.1371\/journal.pone.0008787","article-title":"Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1\/Alhydrogel with and without CPG 7909 in malaria naive adults","volume":"5","author":"Ellis","year":"2010","journal-title":"PLoS One"},{"issue":"August 13 (23\u201324)","key":"10.1016\/j.cytogfr.2011.07.001_bib0235","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1016\/j.vaccine.2004.01.058","article-title":"Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine","volume":"22","author":"Cooper","year":"2004","journal-title":"Vaccine"},{"issue":"April 15 (8)","key":"10.1016\/j.cytogfr.2011.07.001_bib0240","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1086\/533467","article-title":"CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years","volume":"46","author":"Cooper","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"July 1 (1)","key":"10.1016\/j.cytogfr.2011.07.001_bib0245","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/653112","article-title":"Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial","volume":"51","author":"Sogaard","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"March (3)","key":"10.1016\/j.cytogfr.2011.07.001_bib0250","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1172\/JCI23373","article-title":"Rapid and strong human CD8+T cell responses to vaccination with peptide IFA, and CpG oligodeoxynucleotide 7909","volume":"115","author":"Speiser","year":"2005","journal-title":"J Clin Invest"},{"issue":"October (8)","key":"10.1016\/j.cytogfr.2011.07.001_bib0255","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/CJI.0b013e3181f1d614","article-title":"Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients","volume":"33","author":"Speiser","year":"2010","journal-title":"J Immunother"},{"issue":"May 22 (21)","key":"10.1016\/j.cytogfr.2011.07.001_bib0260","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.1073\/pnas.0703395104","article-title":"Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody\/Th1 responses and CD8 T cells through cross-priming","volume":"104","author":"Valmori","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"June 10 (11)","key":"10.1016\/j.cytogfr.2011.07.001_bib0265","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/jm100358c","article-title":"Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues","volume":"53","author":"Shukla","year":"2010","journal-title":"J Med Chem"},{"issue":"March 11 (10)","key":"10.1016\/j.cytogfr.2011.07.001_bib0270","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1182\/blood-2009-08-238543","article-title":"Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists","volume":"115","author":"Rajagopal","year":"2010","journal-title":"Blood"},{"issue":"September (9)","key":"10.1016\/j.cytogfr.2011.07.001_bib0275","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1517\/14712598.4.9.1541","article-title":"First international symposium on melanoma and other cutaneous malignancies","volume":"4","author":"Tarhini","year":"2004","journal-title":"Expert Opin Biol Ther"},{"issue":"July 1 (1)","key":"10.1016\/j.cytogfr.2011.07.001_bib0280","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4049\/jimmunol.181.1.776","article-title":"Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant","volume":"181","author":"Adams","year":"2008","journal-title":"J Immunol"},{"issue":"March 30 (7)","key":"10.1016\/j.cytogfr.2011.07.001_bib0285","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.bjc.6605611","article-title":"Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia","volume":"102","author":"Daayana","year":"2010","journal-title":"Br J Cancer"},{"issue":"June (6)","key":"10.1016\/j.cytogfr.2011.07.001_bib0290","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1586\/erv.11.20","article-title":"CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer","volume":"10","author":"Morse","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"June (2)","key":"10.1016\/j.cytogfr.2011.07.001_bib0295","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/08977190410001700989","article-title":"FLT3: receptor and ligand","volume":"22","author":"Drexler","year":"2004","journal-title":"Growth Factors"},{"issue":"February 15 (4)","key":"10.1016\/j.cytogfr.2011.07.001_bib0300","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood.V91.4.1101","article-title":"c-kit ligand and Flt3 ligand: stem\/progenitor cell factors with overlapping yet distinct activities","volume":"91","author":"Lyman","year":"1998","journal-title":"Blood"},{"issue":"November 1 (5)","key":"10.1016\/j.cytogfr.2011.07.001_bib0305","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1084\/jem.184.5.1953","article-title":"Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified","volume":"184","author":"Maraskovsky","year":"1996","journal-title":"J Exp Med"},{"issue":"June","key":"10.1016\/j.cytogfr.2011.07.001_bib0310","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1196\/annals.1392.015","article-title":"Flt3 in regulation of type I interferon-producing cell and dendritic cell development","volume":"1106","author":"Onai","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"September (9)","key":"10.1016\/j.cytogfr.2011.07.001_bib0315","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"April 15 (8)","key":"10.1016\/j.cytogfr.2011.07.001_bib0320","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1182\/blood.V99.8.2845","article-title":"Flt3 ligand as a vaccine adjuvant in association with HER-2\/neu peptide-based vaccines in patients with HER-2\/neu-overexpressing cancers","volume":"99","author":"Disis","year":"2002","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.cytogfr.2011.07.001_bib0325","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1023\/A:1021904432489","article-title":"Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant","volume":"23","author":"McNeel","year":"2003","journal-title":"J Clin Immunol"},{"issue":"September 23","key":"10.1016\/j.cytogfr.2011.07.001_bib0330","first-page":"9","article-title":"The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand","volume":"4","author":"Shackleton","year":"2004","journal-title":"Cancer Immun"},{"issue":"December 7 (11)","key":"10.1016\/j.cytogfr.2011.07.001_bib0335","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1084\/jem.188.11.2075","article-title":"Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant","volume":"188","author":"Pulendran","year":"1998","journal-title":"J Exp Med"},{"issue":"June (6)","key":"10.1016\/j.cytogfr.2011.07.001_bib0340","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1189\/jlb.1103588","article-title":"Short-term Flt3L treatment effectively mobilizes functional macaque dendritic cells","volume":"75","author":"Teleshova","year":"2004","journal-title":"J Leukoc Biol"},{"issue":"November (11)","key":"10.1016\/j.cytogfr.2011.07.001_bib0345","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/IAI.00322-07","article-title":"Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis","volume":"75","author":"Triccas","year":"2007","journal-title":"Infect Immun"},{"issue":"August 18 (35)","key":"10.1016\/j.cytogfr.2011.07.001_bib0350","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1016\/j.vaccine.2008.06.044","article-title":"Recombinant DNA vaccine of the early secreted antigen ESAT-6 by Mycobacterium tuberculosis and Flt3 ligand enhanced the cell-mediated immunity in mice","volume":"26","author":"Xu","year":"2008","journal-title":"Vaccine"},{"issue":"November 28 (44)","key":"10.1016\/j.cytogfr.2011.07.001_bib0355","doi-asserted-by":"crossref","first-page":"7118","DOI":"10.3748\/wjg.v12.i44.7118","article-title":"Genetic vaccination with Flt3-L and GM-CSF as adjuvants: Enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection","volume":"12","author":"Encke","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"December 18 (3)","key":"10.1016\/j.cytogfr.2011.07.001_bib0360","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbrc.2009.10.081","article-title":"Sublingual vaccination with outer membrane protein of Porphyromonas gingivalis and Flt3 ligand elicits protective immunity in the oral cavity","volume":"390","author":"Zhang","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"April 30 (18)","key":"10.1016\/j.cytogfr.2011.07.001_bib0365","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1182\/blood-2008-10-185470","article-title":"Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens","volume":"113","author":"Decker","year":"2009","journal-title":"Blood"},{"issue":"August 15 (16)","key":"10.1016\/j.cytogfr.2011.07.001_bib0370","first-page":"4677","article-title":"Interleukin-12: biological properties and clinical application","volume":"13","author":"Del","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cytogfr.2011.07.001_bib0375","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.0105-2896.2004.00214.x","article-title":"IL-12 and IL-23: master regulators of innate and adaptive immunity","volume":"December (202)","author":"Langrish","year":"2004","journal-title":"Immunol Rev"},{"issue":"March 1 (5)","key":"10.1016\/j.cytogfr.2011.07.001_bib0380","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1158\/1078-0432.CCR-06-1603","article-title":"Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients","volume":"13","author":"Hansson","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"January 1 (1)","key":"10.1016\/j.cytogfr.2011.07.001_bib0385","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1158\/1078-0432.CCR-06-1450","article-title":"Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease","volume":"13","author":"Hamid","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"November (6)","key":"10.1016\/j.cytogfr.2011.07.001_bib0390","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/00002371-200411000-00005","article-title":"Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12","volume":"27","author":"Kikuchi","year":"2004","journal-title":"J Immunother"},{"issue":"July 16 (7)","key":"10.1016\/j.cytogfr.2011.07.001_bib0395","article-title":"Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma","volume":"3","author":"Cebon","year":"2003","journal-title":"Cancer Immun"},{"issue":"June 15 (12)","key":"10.1016\/j.cytogfr.2011.07.001_bib0400","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2003.12.144","article-title":"Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma","volume":"21","author":"Peterson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"September 15 (18)","key":"10.1016\/j.cytogfr.2011.07.001_bib0405","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2001.19.18.3836","article-title":"Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma","volume":"19","author":"Lee","year":"2001","journal-title":"J Clin Oncol"},{"issue":"March (3 Suppl)","key":"10.1016\/j.cytogfr.2011.07.001_bib0410","first-page":"895s","article-title":"Immunization of HLA-A2+melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12","volume":"7","author":"Gajewski","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"October 31","key":"10.1016\/j.cytogfr.2011.07.001_bib0415","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1749-6632.1996.tb52698.x","article-title":"Interleukin-12 as adjuvant in peptide vaccines","volume":"795","author":"O\u2019Toole","year":"1996","journal-title":"Ann N Y Acad Sci"},{"issue":"June (1\u20132)","key":"10.1016\/j.cytogfr.2011.07.001_bib0420","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1386-6532(99)00008-6","article-title":"Enhanced protection against viral infection by co-administration of plasmid DNA coding for viral antigen and cytokines in mice","volume":"13","author":"Operschall","year":"1999","journal-title":"J Clin Virol"},{"issue":"March 6 (10)","key":"10.1016\/j.cytogfr.2011.07.001_bib0425","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.vaccine.2005.09.051","article-title":"Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates","volume":"24","author":"Parker","year":"2006","journal-title":"Vaccine"},{"issue":"October (4)","key":"10.1016\/j.cytogfr.2011.07.001_bib0430","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1086\/314996","article-title":"Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity","volume":"180","author":"Arulanandam","year":"1999","journal-title":"J Infect Dis"},{"issue":"April 1 (7)","key":"10.1016\/j.cytogfr.2011.07.001_bib0435","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.4049\/jimmunol.164.7.3698","article-title":"Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines","volume":"164","author":"Arulanandam","year":"2000","journal-title":"J Immunol"},{"issue":"May 22 (21)","key":"10.1016\/j.cytogfr.2011.07.001_bib0440","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1016\/j.vaccine.2005.08.011","article-title":"The use of Th1 cytokines IL-12 and IL-23, to modulate the immune response raised to a DNA vaccine delivered by gene gun","volume":"24","author":"Williman","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.cytogfr.2011.07.001_bib0445","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1089\/vim.2005.18.244","article-title":"Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge","volume":"18","author":"Galarza","year":"2005","journal-title":"Viral Immunol"},{"issue":"April 16 (13\u201314)","key":"10.1016\/j.cytogfr.2011.07.001_bib0450","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.vaccine.2004.01.036","article-title":"Co-immunization with plasmid IL-12 generates a strong T-cell memory response in mice","volume":"22","author":"Chattergoon","year":"2004","journal-title":"Vaccine"},{"issue":"September 17 (37\u201338)","key":"10.1016\/j.cytogfr.2011.07.001_bib0455","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.1016\/j.vaccine.2007.07.005","article-title":"Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis","volume":"25","author":"Hwang","year":"2007","journal-title":"Vaccine"},{"issue":"February (1)","key":"10.1016\/j.cytogfr.2011.07.001_bib0460","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/152581601750098471","article-title":"Mobilization of dendritic cells and NK cells in non-Hodgkin's lymphoma patients mobilized with different growth factors","volume":"10","author":"Gazitt","year":"2001","journal-title":"J Hematother Stem Cell Res"},{"issue":"August (4)","key":"10.1016\/j.cytogfr.2011.07.001_bib0465","first-page":"257","article-title":"Human recombinant granulocyte-macrophage colony-stimulating factor augments viability and cytotoxic activities of human monocyte-derived macrophages in long-term cultures","volume":"10","author":"Robin","year":"1991","journal-title":"Lymphokine Cytokine Res"},{"issue":"September (9)","key":"10.1016\/j.cytogfr.2011.07.001_bib0470","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1080\/10428190802216731","article-title":"GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas","volume":"49","author":"Schuster","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"July (7)","key":"10.1016\/j.cytogfr.2011.07.001_bib0475","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1634\/stemcells.2005-0492","article-title":"Granulocyte colony-stimulating factor mobilizes more dendritic cell subsets than granulocyte-macrophage colony-stimulating factor with no polarization of dendritic cell subsets in normal donors","volume":"24","author":"Shaughnessy","year":"2006","journal-title":"Stem Cells"},{"issue":"April 18 (8)","key":"10.1016\/j.cytogfr.2011.07.001_bib0480","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jnci\/82.8.697","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial","volume":"82","author":"Steis","year":"1990","journal-title":"J Natl Cancer Inst"},{"issue":"July 15 (2)","key":"10.1016\/j.cytogfr.2011.07.001_bib0485","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4049\/jimmunol.145.2.607","article-title":"Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture Analysis of macrophage antibody-dependent cellular cytotoxicity","volume":"145","author":"Young","year":"1990","journal-title":"J Immunol"},{"issue":"June 15 (12)","key":"10.1016\/j.cytogfr.2011.07.001_bib0490","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V81.12.3474.3474","article-title":"Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: application in bone marrow transplantation","volume":"81","author":"Charak","year":"1993","journal-title":"Blood"},{"issue":"September 1 (5)","key":"10.1016\/j.cytogfr.2011.07.001_bib0495","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.4049\/jimmunol.145.5.1483","article-title":"Evaluation of the antibody-dependent cytotoxic capabilities of individual human monocytes. Role of Fc gamma RI and Fc gamma RII and the effects of cytokines at the single cell level","volume":"145","author":"Connor","year":"1990","journal-title":"J Immunol"},{"issue":"June 1 (11)","key":"10.1016\/j.cytogfr.2011.07.001_bib0500","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.4049\/jimmunol.164.11.5746","article-title":"Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages","volume":"164","author":"Keler","year":"2000","journal-title":"J Immunol"},{"issue":"November (3)","key":"10.1016\/j.cytogfr.2011.07.001_bib0505","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s002620050513","article-title":"Pharmacological administration of granulocyte\/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen","volume":"47","author":"Samanci","year":"1998","journal-title":"Cancer Immunol Immunother"},{"issue":"March (2)","key":"10.1016\/j.cytogfr.2011.07.001_bib0510","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/00002371-199903000-00008","article-title":"Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma","volume":"22","author":"Leong","year":"1999","journal-title":"J Immunother"},{"issue":"June 1 (4)","key":"10.1016\/j.cytogfr.2011.07.001_bib0515","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/(SICI)1097-0045(19990601)39:4<291::AID-PROS10>3.0.CO;2-9","article-title":"GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial","volume":"39","author":"Simmons","year":"1999","journal-title":"Prostate"},{"issue":"May (5)","key":"10.1016\/j.cytogfr.2011.07.001_bib0520","first-page":"1181","article-title":"The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma","volume":"7","author":"von","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"December 13 (3\u20134)","key":"10.1016\/j.cytogfr.2011.07.001_bib0525","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0264-410X(02)00463-2","article-title":"A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: effect on cellular and humoral immune responses","volume":"21","author":"Somani","year":"2002","journal-title":"Vaccine"},{"issue":"January 1 (1)","key":"10.1016\/j.cytogfr.2011.07.001_bib0530","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/cncr.11045","article-title":"Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma","volume":"97","author":"Weber","year":"2003","journal-title":"Cancer"},{"issue":"March 20 (2)","key":"10.1016\/j.cytogfr.2011.07.001_bib0535","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/ijc.10961","article-title":"Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides","volume":"104","author":"Scheibenbogen","year":"2003","journal-title":"Int J Cancer"},{"issue":"July (4)","key":"10.1016\/j.cytogfr.2011.07.001_bib0540","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00002371-200307000-00009","article-title":"Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group","volume":"26","author":"Dillman","year":"2003","journal-title":"J Immunother"},{"issue":"May 15 (10)","key":"10.1016\/j.cytogfr.2011.07.001_bib0545","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1158\/1078-0432.CCR-03-0706","article-title":"Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte\/macrophage colony-stimulating factor","volume":"10","author":"Ullenhag","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"January 26 (5\u20136)","key":"10.1016\/j.cytogfr.2011.07.001_bib0550","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.vaccine.2003.08.021","article-title":"Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor","volume":"22","author":"Neidhart","year":"2004","journal-title":"Vaccine"},{"issue":"July (4)","key":"10.1016\/j.cytogfr.2011.07.001_bib0555","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/01.cji.0000208258.79005.5f","article-title":"A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients","volume":"29","author":"Barrio","year":"2006","journal-title":"J Immunother"},{"issue":"July 15 (2)","key":"10.1016\/j.cytogfr.2011.07.001_bib0560","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/cncr.23561","article-title":"Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity","volume":"113","author":"Safdar","year":"2008","journal-title":"Cancer"},{"issue":"October (4)","key":"10.1016\/j.cytogfr.2011.07.001_bib0565","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1600-0609.2007.00912.x","article-title":"Hepatitis B virus vaccine in lymphoproliferative disorders: a prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant","volume":"79","author":"Yagci","year":"2007","journal-title":"Eur J Haematol"},{"issue":"August 2 (34)","key":"10.1016\/j.cytogfr.2011.07.001_bib0570","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1016\/j.vaccine.2010.06.030","article-title":"Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220","volume":"28","author":"Overton","year":"2010","journal-title":"Vaccine"},{"issue":"January 7 (2)","key":"10.1016\/j.cytogfr.2011.07.001_bib0575","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.vaccine.2008.10.051","article-title":"Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial","volume":"27","author":"Spearman","year":"2009","journal-title":"Vaccine"},{"issue":"December 15 (12)","key":"10.1016\/j.cytogfr.2011.07.001_bib0580","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.4049\/jimmunol.179.12.8418","article-title":"Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs","volume":"179","author":"Ryan","year":"2007","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.cytogfr.2011.07.001_bib0585","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.imbio.2009.04.002","article-title":"Investigation of immunogenic effect of the BCG priming and Ag85A-GM-CSF boosting in Balb\/c mice model","volume":"215","author":"Dou","year":"2010","journal-title":"Immunobiology"},{"issue":"January (1)","key":"10.1016\/j.cytogfr.2011.07.001_bib0590","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/eji.200939665","article-title":"Modulation of pulmonary DC function by vaccine-encoded GM-CSF enhances protective immunity against Mycobacterium tuberculosis infection","volume":"40","author":"Nambiar","year":"2010","journal-title":"Eur J Immunol"},{"issue":"April (Pt 2)","key":"10.1016\/j.cytogfr.2011.07.001_bib0595","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1042\/BST0340283","article-title":"Manipulation of dendritic cells for host defence against intracellular infections","volume":"34","author":"McCormick","year":"2006","journal-title":"Biochem Soc Trans"},{"issue":"March (3)","key":"10.1016\/j.cytogfr.2011.07.001_bib0600","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.micinf.2007.11.009","article-title":"T cell epitope-based peptide-DNA dual vaccine induces protective immunity against Schistosoma japonicum infection in C57BL\/6J mice","volume":"10","author":"Zhang","year":"2008","journal-title":"Microbes Infect"},{"issue":"8","key":"10.1016\/j.cytogfr.2011.07.001_bib0605","doi-asserted-by":"crossref","first-page":"e797","DOI":"10.1371\/journal.pntd.0000797","article-title":"Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice","volume":"4","author":"Gupta","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"July 20 (29)","key":"10.1016\/j.cytogfr.2011.07.001_bib0610","doi-asserted-by":"crossref","first-page":"13010","DOI":"10.1073\/pnas.1006662107","article-title":"Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant","volume":"107","author":"Li","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"June 8 (28)","key":"10.1016\/j.cytogfr.2011.07.001_bib0615","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1016\/j.vaccine.2009.03.090","article-title":"Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine","volume":"27","author":"Kopecky-Bromberg","year":"2009","journal-title":"Vaccine"},{"issue":"May 26 (25\u201326)","key":"10.1016\/j.cytogfr.2011.07.001_bib0620","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1016\/j.vaccine.2009.01.083","article-title":"Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens","volume":"27","author":"Courtney","year":"2009","journal-title":"Vaccine"},{"issue":"May 26 (25\u201326)","key":"10.1016\/j.cytogfr.2011.07.001_bib0625","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1016\/j.vaccine.2009.01.047","article-title":"Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy","volume":"27","author":"Thapa","year":"2009","journal-title":"Vaccine"},{"issue":"July 12 (31)","key":"10.1016\/j.cytogfr.2011.07.001_bib0630","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1016\/j.vaccine.2010.03.079","article-title":"Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV","volume":"28","author":"Zhang","year":"2010","journal-title":"Vaccine"},{"issue":"February (2)","key":"10.1016\/j.cytogfr.2011.07.001_bib0635","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nm1183","article-title":"Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo","volume":"11","author":"Hanks","year":"2005","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.cytogfr.2011.07.001_bib0640","first-page":"25","article-title":"Emerging vaccine therapy approaches for prostate cancer","volume":"12","author":"Sonpavde","year":"2010","journal-title":"Rev Urol"},{"issue":"October (10)","key":"10.1016\/j.cytogfr.2011.07.001_bib0645","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/jmv.21566","article-title":"Rapid immunity to vaccination with woodchuck hepatitis virus surface antigen using cationic liposome\u2013DNA complexes as adjuvant","volume":"81","author":"Cote","year":"2009","journal-title":"J Med Virol"},{"issue":"June (24)","key":"10.1016\/j.cytogfr.2011.07.001_bib0650","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1016\/j.vaccine.2007.04.019","article-title":"IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: a single-blind phase I study","volume":"11\u201325","author":"Brignone","year":"2007","journal-title":"Vaccine"},{"issue":"June 4 (23)","key":"10.1016\/j.cytogfr.2011.07.001_bib0655","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/blood-2008-11-190520","article-title":"Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity","volume":"113","author":"Morrow","year":"2009","journal-title":"Blood"}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610111000323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610111000323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T10:21:53Z","timestamp":1712744513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610111000323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":131,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S1359610111000323"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2011.07.001","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}